Multiple Myeloma Stem Cell Transplant Survival Rate

Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma.

Multiple myeloma stem cell transplant survival rate.

Multiple myeloma isn t considered curable but symptoms wax and wane. Autologous stem cell transplantation autosct has an important role in the treatment of patients with symptomatic multiple myeloma mm. A relative survival rate compares people with the same type and stage of cancer to people in the overall population. Findings from a phase 3 clinical trial note that patients with multiple myeloma who receive upfront autologous stem cell transplant asct typically live longer without disease.

The transplant of this kind is the standard treatment for patients with various myeloma. The long term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines a large review study reports. Stem cell transplant is commonly used to treat multiple myeloma. In some cases a bone marrow or stem cell transplant is an option.

A population based study published correction appears in blood. Before the transplant drug treatment is used to reduce the number of myeloma cells in the patient s body. For example if the 5 year relative survival rate for a specific stage of multiple myeloma is 60 it means that people who have that cancer are on average about 60 as likely as people who don t have that cancer to live for. To protect them your doctor removes stem cells.

See drug therapy for multiple myeloma stem cell transplants sct can be autologous or allogeneic. Treatment options for myeloma have expanded in. All things considered while the autologous transplant can make the myeloma go away for a period of time even years it does not cure the growth and inevitably the myeloma back. Multiple myeloma survival rate after stem cell transplant.

The widespread use of high dose therapy and autologous stem cell transplantation asct as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma mm enabling long term survival. There can be a long period of dormancy that could. Patients with multiple myeloma live longer without their disease progressing if they get a stem cell transplant compared with patients who received chemotherapy alone.